We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trading under new ticker symbol "BAXS" to begin June 3, 2013 Completes financing of $17.2M at $2.28/share Two directors and Vice President of Operations appointed from former Baxano, Inc...
Abbott Laboratories (ABT) recently announced that it received CE Mark in Europe for its drug eluting stent – Xience Xpedition 48 Everolimus Eluting Coronary Stent System. Xience...
- First quarter revenues were $3.1 million - - Net loss per share was $0.26 for the quarter - - Excluding special items, net loss per share was $0.21 for the quarter* - - Acquisition of...
RALEIGH, N.C., April 26, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release first quarter 2013 financial and operating results, and provide an update on...
RALEIGH, N.C., March 14, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in the Canaccord Genuity Musculoskeletal conference in March. Ken Reali...
- Fourth quarter revenues were $4.1 million - - Net loss per share was $0.44 for the quarter β - Excluding special items, net loss per share was $0.20 for the quarter* - RALEIGH, N.C...
WILMINGTON, N.C., Feb. 21, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it will participate in two healthcare conferences in February and March, 2013. Ken Reali...
WILMINGTON, N.C., Feb. 20, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON) announced today that it plans to release fourth quarter 2012 financial and operating results after market close on...
WILMINGTON, N.C., Feb. 19, 2013 (GLOBE NEWSWIRE) -- TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing spine products to treat degenerative...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions